NASDAQ:CDNA - CareDx Stock Price, Forecast & News

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

CareDx Inc (NASDAQ:CDNA) posted its quarterly earnings results on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.01. The business earned $33.80 million during the quarter, compared to analyst estimates of $33.14 million. CareDx had a negative net margin of 18.25% and a negative return on equity of 21.92%. CareDx's revenue for the quarter was up 59.4% compared to the same quarter last year. View CareDx's Earnings History.

CareDx is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for CareDx.

CareDx will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

CareDx issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $127-127.3 million, compared to the consensus revenue estimate of $125.4 million.

5 Wall Street analysts have issued 1-year target prices for CareDx's shares. Their forecasts range from $43.00 to $63.00. On average, they expect CareDx's share price to reach $53.00 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price. View Analyst Price Targets for CareDx.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

News headlines about CDNA stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CareDx earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for CareDx.

CareDx saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,820,000 shares, an increase of 26.5% from the January 15th total of 3,810,000 shares. Based on an average daily volume of 776,300 shares, the short-interest ratio is presently 6.2 days. Approximately 11.8% of the shares of the company are sold short. View CareDx's Current Options Chain.

Some companies that are related to CareDx include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD) and Miragen Therapeutics (MGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include EXACT Sciences (EXAS), Roku (ROKU), Alibaba Group (BABA), Aduro BioTech (ADRO), Advanced Micro Devices (AMD), Tandem Diabetes Care (TNDM), Micron Technology (MU), Square (SQ), NVIDIA (NVDA) and AbbVie (ABBV).

CareDx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (12.22%), State Street Corp (6.04%), Credit Suisse AG (3.24%), Casdin Capital LLC (2.83%), Gagnon Securities LLC (2.33%) and Lord Abbett & CO. LLC (1.89%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View Institutional Ownership Trends for CareDx.

CDNA stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, State Street Corp, Goldman Sachs Group Inc., Rafferty Asset Management LLC, UBS Group AG, Citigroup Inc., AQR Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Sasha King and William A Hagstrom. View Insider Buying and Selling for CareDx.

CDNA stock was acquired by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Fred Alger Management LLC, Sumitomo Mitsui Trust Holdings Inc., Schonfeld Strategic Advisors LLC, Nikko Asset Management Americas Inc., ARK Investment Management LLC, Bamco Inc. NY and Royce & Associates LP. View Insider Buying and Selling for CareDx.

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDNA stock can currently be purchased for approximately $27.15.

CareDx has a market capitalization of $1.15 billion and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.View Additional Information About CareDx.

The official website for CareDx is http://www.caredxinc.com/.

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]